Clinical development—Our preclinical studies have demonstrated that sovateltide mediated ETBR stimulation in AD animal models is highly beneficial, and its testing in clinical trials would be useful for developing a novel agent for the treatment of AD. This evidence concerns the gene EDNRB and Alzheimer disease.